Article info
PDFLetters
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody
- Correspondence to Professors Chunde Bao and Qiang Guo, Rhematology Department of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.145, Shangdong (c) Road, 200001, Shanghai, China; baochunde_1678{at}126.com and marquisjerry{at}126.com
Citation
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody
Publication history
- Received January 23, 2014
- Revised March 16, 2014
- Accepted March 22, 2014
- First published April 16, 2014.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions